Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Imperial College London, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:London
Treatments:ChemotherapyHospital:Imperial College London
Drugs:Journal:Link
Date:Jan 2014

Description:

Patients:
This phase 3 study involved platinum-resistant ovarian cancer patients who were separated into two treatment groups. Group A consisted of 70 women with a median age of 57.5 years, while group B had 72 women with a median age of 59 years.

Treatment:
Patients in group A were given chemotherapy with carboplatin and phenoxodiol.
Patients in group B were given chemotherapy with carboplatin and a placebo.

Toxicities:
In group A, grade 5 adverse events were reported due to disease progression. Grade 3 or higher neutropenia, thrombocytopenia, and vomiting were also reported.

In group B, grade 5 adverse events were reported due to disease progression. Grade 3 or higher neutropenia and thrombocytopenia were also reported.

Results:
The median overall survival rates for groups A and B were 8.8 and 10.5 months, respectively.

Support:
This study was supported by the pharmaceutical company Marshall Edwards, Inc.

Correspondence: Dr. Hani Gabra; email: [email protected]



Back